Abstracts tagged "B-Cell Targets"

Abstract Number: 2442 • ACR Convergence 2025
Reduction in Extrafollicular B Cell Responses in SLE Patients after CAR T Cell Therapy
Danae-Mona Nöthling¹, Kirill Anoshkin¹, Panagiotis Garantziotis¹, Laura Bucci¹, Tobias Rothe², Jule Taubmann³, Futoshi Iwata¹, Melanie Hagen¹, Andreas Wirsching¹, Simon Völkl⁴, Fabian Müller⁵, Aline Bozec¹, Andreas Mackensen⁶, Georg Schett⁷ and Ricardo Grieshaber-Bouyer⁸, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ²Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlagen, Germany, ³Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁴Department of Medicine ⁵ - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁵University Hospital of Erlangen, Erlangen, Germany, ⁶Department of Medicine ⁵ - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, ⁷Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ⁸University Hospital Erlangen, Erlangen, Germany
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by aberrant B cell activation and autoantibody production. CD19-targeted chimeric antigen receptor (CAR) T-cell therapy induces a short,…
Abstract Number: 1532 • ACR Convergence 2025
Preliminary Safety, Efficacy, and Cellular Kinetics of CTA313, a CD19/BCMA Dual-Targeted Universal CAR-T Therapy, for Active Systemic Lupus Erythematosus
Hanwei Wang¹, Yue Xie², Guojiao Yang³, Lu Han³, Jiangtao Ren⁴, Yali Zhou⁴, Wengang Ge³, Jan Davidson-Moncada⁴ and Huan Zhou⁵, ¹The Third People’s Hospital of Bengbu, Beng bu, China (People's Republic), ²Bioheng Therapeutics Limited, Nan Jing Shi, China (People's Republic), ³Bioheng Therapeutics Co., Limited, Nanjing, China (People's Republic), ⁴Bioheng Therapeutics Co., Limited, Nan Jing, China (People's Republic), ⁵Clinical Research Hospital of the First Affiliated Hospital of Anhui Medical University, Hefei, China (People's Republic)
Background/Purpose: SLE is characterized by B cell activation, autoantibody production and autoreactivity. Recently, CAR-T therapy has emerged as a promising strategy to deplete autoreactive B…
Abstract Number: 0913 • ACR Convergence 2025
Potent and Selective Oral IRF5 Degrader, KT-579, Demonstrates In Vitro and In Vivo Activity Comparable or Superior to Approved or Clinically Active Agents in Human Cellular Assays and Lupus Efficacy Models
Veronica Campbell¹, Yi Zhang¹, Virginia Massa¹, Jordan Leedberg¹, Erik Corcoran¹, Emily Lurier¹, Ryan Camire², Chris Carroll¹, Chris Ho¹, Dapeng Chen¹, Bradley Enerson¹, Revonda Mehovic¹, Ziyan Zhao¹, Lincoln Howarth¹, Susanne Breitkopf¹, Sarah Martinez¹, Melissa Ford¹, Xue Fei¹, Murugappan Sathappa¹, Juliet Williams³, Matthew Weiss³, Arsalan Shabbir³ and Nello Mainolfi⁴, ¹Kymera Therapeutics, Watertown, MA ⁰²⁴⁷², ²Kymera Therapeutics, Watertown, MA ⁰²⁴⁷², MA, ³Kymera Therapeutics, Watertown, ⁴Kymera Therapeutics, Watertown, MA
Background/Purpose: IRF5 is a transcription factor and regulator of immune responses activated downstream of pattern recognition receptors, in particular endosomal toll-like receptors (TLR), TLR7, TLR8…
Abstract Number: 0262 • ACR Convergence 2025
Preclinical Characterization of ABB071 – a Humanized anti-CD180 Antibody that Modulates Multiple Pro-inflammatory Immune Pathways for the Treatment of Autoimmune and Inflammatory Disorders
Margaret McDaniel, Brenda Stevens, Socheath Khim, Alan Wahl, Che-Leung Law and Edward Clark, Abacus Bioscience, Seattle, WA
Background/Purpose: CD180 is a Toll-like receptor (TLR) homolog expressed on antigen-presenting cells (APCs): B cells, dendritic cells, monocytes, and macrophages. While the extracellular domain of…
Abstract Number: 0003 • ACR Convergence 2025
In Vivo Generation of anti-CD19 CAR T Cells Utilizing Circular RNA Encapsulated in Targeted Lipid Nanoparticles
Xiaoyu Pan¹, Xiaoning Wang¹, Zhihao Chen¹, Xiaowen Zou¹, Siqi Li¹, Jian Ye¹, Fei Lin¹, Yang He¹, Edo Kon², Peng Zhu¹, Mengyun Chen¹ and Weiyi Zhang¹, ¹RiboX Therapeutics, Shanghai, China (People's Republic), ²RiboX Therapeutics, Cambridge, MA
Background/Purpose: Chimeric Antigen Receptor (CAR) T-cell therapy has revolutionized cancer treatment and shown promise in addressing autoimmune diseases. However, current ex vivo CAR T-cell therapies…
Abstract Number: 2695 • ACR Convergence 2025
B-cell depletion and lymphoid follicle disruption upon different B-cell depleting agents
Carlo Tur¹, Markus Eckstein², Laura Bucci¹, Janina Auth³, Christina Bergmann¹, Simon Rauber⁴, Melanie Hagen¹, Danae-Mona Nöthling¹, Sebastian Böltz¹, Andreas Wirsching¹, Filippo Fagni⁵, Giulia Corte⁶, Panagiotis Garantziotis¹, Jule Taubmann⁷, jochen wacker¹, Andreas Ramming⁸, Maria Antonietta D'Agostino⁹, Arndt Hartmann¹⁰, Fabian Müller¹¹, Andreas Mackensen¹², Ricardo Grieshaber-Bouyer¹³, Georg Schett¹⁴, Aline Bozec¹ and Maria Gabriella Raimondo¹, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ²Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander- Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ³Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ⁴Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Bayern, Germany, ⁵Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Bayern, Germany, ⁶- Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ⁷Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁸Department of Internal Medicine ³, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) & Universitätsklinikum Erlangen, Erlangen, Germany, ⁹Division of Rheumatology and Clinical Immunology - Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ¹⁰Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander- Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ¹¹University Hospital of Erlangen, Erlangen, Germany, ¹²Department of Medicine ⁵ - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, ¹³University Hospital Erlangen, Erlangen, Germany, ¹⁴Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany
Background/Purpose: Advanced protein-based therapies targeting B-cells, including glycoengineered CD20 monoclonal antibody obinutuzumab (OBI) and the CD19/CD3 T-cell engager blinatumumab (BLI), show promise for managing severe…
Abstract Number: 2425 • ACR Convergence 2025
Neutrophil Transcriptomics in SLE: Exploring Intrinsic, Ex Vivo Adaptation, and CAR-T Cell Therapy-Induced Changes
Ehsan Dehdashtian¹, Stefania Gallucci², Guangnan Hu³, Dominic Borie⁴ and Roberto Caricchio⁵, ¹UMass Chan Medical School, Worcester, MA, ²Temple University School of Medicine, Worcester, MA, ³UMass Chan School of Medicine, Worcester, MA, ⁴Kyverna Therapeutics, Emeryville, CA, ⁵University of Massachusetts Chan Medical School, Worcester, MA
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by dysregulation of the adaptive and innate immune systems. Neutrophils, key players in innate immunity,…
Abstract Number: 1529 • ACR Convergence 2025
Updated Phase 1 Trial Data Assessing the Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BMS-986353 (CC-97540), a CD19-directed Chimeric Antigen Receptor T Cell Therapy Using a Next-Generation Process for Severe, Refractory SLE
Georg Schett¹, David Simon², Margrit Wiesendanger³, Anca Askanase⁴, Vikas Majithia⁵, Neil Kramer⁶, Jacques Morel⁷, Philip J. Mease⁸, Ellen De Langhe⁹, Amit Saxena¹⁰, dominique Farge¹¹, Alain Lescoat¹², Alisha Desai¹³, Griff McTume¹⁴, Whitney Handy¹⁴, Sharmila Das¹³, Jerill Thorpe¹⁴, Alexis Melton¹⁴, Ashley Koegel¹⁴ and Emily Littlejohn¹⁵, ¹Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ²Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Germany, ³Icahn School of Medicine at Mount Sinai, New York, NY, ⁴Columbia University Medical Center, New York, NY, ⁵Mayo Clinic Hospital, Jacksonville, FL, ⁶Overlook Medical Center; Atlantic Medical Group, Atlantic Health System, Summit, NJ, ⁷CHU and University of Montpellier, Montpellier, France, ⁸Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ⁹University Hospitals Leuven, Leuven, Belgium, ¹⁰Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, ¹¹Hôpital Saint-Louis, Paris, France, ¹²CHU Rennes University Hospital, Rennes, France, ¹³Bristol Myers Squibb, Princeton, NJ, ¹⁴Bristol Myers Squibb, Princeton, ¹⁵Cleveland Clinic, Cleveland, OH
Background/Purpose: BMS-986353 (CC-97540; CD19 NEX-T) is a CD19-directed chimeric antigen receptor (CAR) T cell therapy that expresses the same CAR as lisocabtagene maraleucel (liso-cel); it…
Abstract Number: 0910 • ACR Convergence 2025
Development of Four Distinct Human IgG4-Producing Mouse Models Recapitulating IgG4-Related Disease
MIN GANG KIM¹, JINA YEO², HEA RIM KANG³, JAE HYUN MOON³, Seon Uk Kim⁴, SeoYoon Ban⁵, MI HYEON KIM⁶ and Eun Young Lee⁷, ¹Seoul National University College of Medicine, Seoul, Republic of Korea, ²Division of Rheumatology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Republic of Korea, ³Seoul National University College of Medicine, Jongno-gu, Seoul, Republic of Korea, ⁴Seoul National University, Jongno-gu, Seoul, Republic of Korea, ⁵Department of Cancer biology, Graduate School of College of Medicine, Seoul National University, Korea, Seoul, Republic of Korea, ⁶Hallym university dongtan sacred heart hospital, Seocho-gu, Seoul, Republic of Korea, ⁷Seoul National University College of Medicine, Seoul, South Korea
Background/Purpose: IgG4-related disease (IgG4RD) is an immune-mediated fibroinflammatory condition characterized by multi-organ involvement, elevated serum IgG4, and IgG4-positive plasma cell infiltrates that form tumor-like lesions…
Abstract Number: 0239 • ACR Convergence 2025
Safety of Rilzabrutinib, a BTK Inhibitor, in Adult Patients with IgG4-related disease (IgG4-RD) in a 52-week Phase 2 Open-label Study
Alireza Meysami¹, Mollie Carruthers², John Stone³, Fernando Martinez-Valle⁴, nicolas schleinitz⁵, Daniela Ghetie⁶, Robert Spiera⁷, Jeea Choi⁸, Leda Mannent⁹ and Owen Hagino⁸, ¹Henry Ford Health, Detroit, MI, ²Vancouver General Hospital, Vancouver, BC, Canada, ³Massachusetts General Hospital , Harvard Medical School, Concord, MA, ⁴Vall d’Hebron Hospital, Barcelona, Spain, ⁵Aix Marseille university, AP-HM, Marseille, France, ⁶Oregon Health and Science University, Portland, OR, ⁷Scleroderma, Vasculitis, and Myositis Center, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ⁸Sanofi, Morristown, NJ, ⁹Sanofi, Gentilly, France
Background/Purpose: IgG4- related disease (IgG4-RD) is a chronic, progressive, immune-mediated fibrotic disease with limited treatment options. Rilzabrutinib is an orally available, reversible, inhibitor of Bruton's…
Abstract Number: 0002 • ACR Convergence 2025
KITE-363: An Autologous Anti-CD19/CD20 CAR-T Product for the Treatment of Autoimmune Rheumatic Diseases
Brian Kim, Christine Lowe, Francisco Flores, Jeremy Margaitis, Alessandro Calo, Stacey Valny, Anna Konecny, Eva Jaghatspanyan, Sean Yoder, Kenneth Ertel, Simone Filosto, Jodi Murakami and David Barrett, Kite, a Gilead Company, Santa Monica, CA
Background/Purpose: B-cell dysregulation is a key factor in the development and progression of autoimmune diseases, and B-cell inhibition has been a cornerstone of treatment for…
Abstract Number: L17 • ACR Convergence 2024
Allogenic CD19 CAR NK Cells Therapy in Refractory Systemic Lupus Erythematosus: An Open-label, Single Arm, Prospective and Interventional Clinical Trial
Yiyi Yu¹, Ruina Kong¹, Xia Xu¹, Suxuan Liu¹, Qian Chen¹, Xiaofang Li², Ming Sun², Jianmin Yang¹, Dongbao Zhao¹ and Jie Gao¹, ¹Changhai Hospital, Shanghai, China, ²Rui Therapeutics, Nanjing, China
Background/Purpose: Treatment of systemic lupus erythematosus (SLE) typically necessitates long-term immunosuppression with hormones, immunosuppressants and biologics. CD19-targeting chimeric antigen receptor (CAR) T cells have shown excellent…
Abstract Number: 0018 • ACR Convergence 2024
Preclinical Analysisof CB-010, an Allogeneic anti-CD19CAR-T Cell Therapywith a PD-1 Knockout, for the Treatment of Patients with Refractory Systemic Lupus Erythematosus (SLE)
Elizabeth Garner, George Kwong, Tristan W Fowler, Heinrich Kufeldt, Brian Kerfs, Julie Kim, Art Aviles, Lynne Alexander, Franco Davi, Chris Holland, Jean-Yves Maziere, Ashraf Garrett, Mara Bryan, Linh Chu, Sarbani Bhaduri, Michele Gerber, Elaine Alambra, Justin Skoble, Tom Kochy, Tonia Nesheiwat, Socorro Portella, Enrique Zudaire and Steven B Kanner, Caribou Biosciences, Berkeley, CA
Background/Purpose: Autologous CD19-directed CAR-T cell therapy has been shown to eradicate aberrant B cells leading to durable clinical responses in SLE patients (Müller 2024; Wang 2024). However, autologous CAR-T cell…
Abstract Number: 0876 • ACR Convergence 2024
C-CAR168 as a Novel Anti-CD20/BCMA Bispecific Autologous CAR-T Therapy for the Treatment of Autoimmune Diseases
jiaqi Huang¹, Xin Yao¹, Xiaobing Luo¹, Xiaoteng Lv², Yutian Wei², Michael Patrick¹, Fei Wang², Yi Hong² and Yihong Yao¹, ¹AbelZeta Inc., Rockville, MD, ²AbelZeta Inc., Shanghai, China (People's Republic)
Background/Purpose: B cells are pivotal in autoimmune disease pathogenesis as they produce autoantibodies and undergo aberrant maturation processes, and B-cell dysregulation and the production of…
Abstract Number: 1753 • ACR Convergence 2024
A Phase 1, Multicenter, Open-Label Study to Establish the Preliminary Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of CC-97540 (BMS-986353), a CD19-directed CAR T Cell Therapy Manufactured Using a Next-generation Process, for Severe, Refractory Autoimmune Diseases
Georg Schett¹, Emily Littlejohn², Neil Kramer³, Amit Saxena⁴, Philip Mease⁵, Margrit Wiesendanger⁶, Fabian Müller⁷, Ran Reshef⁸, Paolo Caimi⁹, Mohamad Cherry¹⁰, Jingmei Hsu⁴, Krish Patel¹¹, Jacques Azzi⁶, Susana Falcon¹², Thomas Ly¹³, Ken Ogasawara¹², Sharmila Das¹², Jerill Thorpe¹⁴, Michael Maldonado¹², Giuseppina Stifano¹², Ashley Koegel¹² and Anca Askanase¹⁵, ¹Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ²Cleveland Clinic, Cleveland, OH, ³Atlantic Medical Group, Atlantic Health System, Morristown, NJ, ⁴NYU Grossman School of Medicine, New York, NY, ⁵Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ⁶Icahn School of Medicine at Mount Sinai, New York, NY, ⁷Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, ⁸Columbia University Irving Medical Center, New York, NY, ⁹Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, ¹⁰Atlantic Health System, Morristown, NJ, ¹¹Center for Blood Disorders and Cellular Therapy, Swedish Cancer Institute, Seattle, WA, ¹²Bristol Myers Squibb, Princeton, NJ, ¹³Bristol Myers Squibb, San Diego, CA, ¹⁴Bristol Myers Squibb, Seattle, WA, ¹⁵Columbia University Medical Center, New York, NY
Background/Purpose: CD19 is an appealing therapeutic target due to its ubiquitous expression on B cells and plasmablasts, which play a key role in the pathogenesis…

« Previous Page
1
…
4
5
6
7
8
…
17
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].